Ptc Therapeutics, INC

PTC Therapeutics announced the completion of its private offering of $550 million in 0% Convertible Senior Notes due 2031, with net proceeds intended for general corporate purposes and repurchasing existing convertible notes.

PTC Therapeutics announced the pricing of a $500 million offering of 0% Convertible Senior Notes due 2031, with proceeds intended to refinance existing 2026 notes.

PTC Therapeutics board member Alethia Young has resigned, transitioning into a one-year consulting role with the company.

PTC Therapeutics shareholders re-elected four directors and ratified the appointment of Ernst & Young LLP as the company's independent auditor.

PTC Therapeutics reported strong Q1 2026 financial results, driven by Sephience, and raised its full-year revenue guidance.

PTC Therapeutics announced positive topline results from the 24-month interim analysis of the PIVOT-HD extension study for votoplam, showing dose-dependent slowing of disease progression in Stage 2 Huntington's disease patients.

PTC Therapeutics announces robust Q2 2026 financial results, with significant revenue growth driven by Sephience, alongside strategic advancements in its pipeline and a strengthened financial position.

PTC Therapeutics reported a significant increase in net product revenue for Q1 2026, driven by Sephience sales, while continuing to advance its diverse pipeline and manage operational expenses.

PTC Therapeutics achieved significant net income and revenue growth in Q3 2025, primarily driven by a $1.0 billion upfront payment from its Novartis collaboration, despite product revenue declines for Translarna and Emflaza.

PTC Therapeutics reported a significant financial turnaround driven by a $1.0 billion upfront payment from Novartis, alongside key regulatory approvals for its PKU treatment, Sephience, despite challenges with Translarna in Europe.

PTC Therapeutics' Q1 2025 results showcase a significant revenue surge due to a collaboration with Novartis, offsetting declines in product sales.

PTC Therapeutics' Q3 2024 results show a decrease in product revenue and an increase in royalty revenue, while facing regulatory challenges for Translarna in Europe.

PTC Therapeutics achieved significant regulatory approvals for Sephience and Kebilidi in 2025, driving substantial revenue growth despite challenges with Translarna's EU marketing authorization.

PTC Therapeutics highlights pipeline advancements, including regulatory submissions for sepiapterin and vatiquinone, while navigating potential challenges to Translarna's marketing authorization in Europe.

PTC Therapeutics has amended its royalty purchase agreement with Royalty Pharma, securing $1 billion upfront for a portion of its Evrysdi royalties and retaining options for further sales.

Hege Elisabeth Sollie-Zetlmayer, a Director of Ptc Therapeutics, Inc., reported multiple transactions in common stock on July 28, 2026.

Pierre Gravier, CHIEF FINANCIAL OFFICER of Ptc Therapeutics, Inc., sold 3,494 shares of common stock on July 14, 2026 for $80.35 per share.

Mary L. Smith, a Director of Ptc Therapeutics, Inc., sold 15,834 shares of common stock on July 9, 2026 for $90.00 per share.

Neil Gregory Almstead, CHIEF TECHNICAL OPS OFFICER of Ptc Therapeutics, Inc., sold 2,464 shares of common stock on July 9, 2026 for $90.25 per share.

Mark Elliott Boulding, Executive VP and CLO of PTC Therapeutics, Inc., reported transactions involving the sale of common stock under a pre-arranged trading plan.

Neil Gregory Almstead, Chief Technical Ops Officer at PTC Therapeutics, reported a series of stock transactions on July 6th and 7th, 2026, involving both acquisitions and dispositions of common stock and stock options.

PTC Therapeutics, Inc. has issued its 2026 proxy statement detailing the upcoming annual meeting, director elections, and executive compensation advisory vote.

PTC Therapeutics announces its 2025 Annual Meeting to be held virtually on June 17, 2025, and provides details on how stockholders can vote on key proposals.

PTC Therapeutics announces its 2025 Annual Meeting of Stockholders to be held virtually on June 17, 2025, featuring director elections, auditor ratification, and executive compensation advisory vote.

PTC Therapeutics announces its 2024 Annual Meeting to be held virtually on June 18, 2024, outlining key voting items for shareholders.

PTC Therapeutics will hold its 2024 Annual Meeting of Stockholders virtually on June 18, 2024, to vote on director elections, auditor ratification, and executive compensation.

The Toronto-Dominion Bank has filed a Schedule 13G, reporting beneficial ownership of 3,025,945 shares, or 3.7%, of PTC Therapeutics, Inc. common stock as of March 31, 2026.

Janus Henderson Group plc has reported beneficial ownership of 7,193,433 shares, representing 8.7% of the outstanding common stock of PTC Therapeutics, Inc., as of March 31, 2026.

Vanguard Capital Management has reported beneficial ownership of 5.17% of PTC Therapeutics Inc.'s common stock as of March 31, 2026.

Vanguard Portfolio Management has reported a beneficial ownership of 5.88% in PTC Therapeutics Inc., holding over 4.87 million shares.

The Vanguard Group has reported a 0% beneficial ownership in PTC Therapeutics Inc. following an internal realignment.

Janus Henderson Group plc has reported a 6.0% beneficial ownership stake in PTC Therapeutics, Inc. common stock.